Recruiting studies: Borderline Resectable Pancreatic Ductal Adenocarcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 1 · 6 location(s) · PanTher Therapeutics · NCT06673017 A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07671339 Targeted Pathway Inhibition in Patients With Pancreatic Cancer
EARLY_Phase 1 · 1 location(s) · OHSU Knight Cancer Institute · NCT04005690 Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy
Phase N/A · 1 location(s) · Emory University · NCT06595160 Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment
NA · 1 location(s) · British Columbia Cancer Agency · NCT06574620 NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial
Phase 2 · 1 location(s) · Roswell Park Cancer Institute · NCT06821997 AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma
Phase N/A · 2 location(s) · Roswell Park Cancer Institute · NCT06320717 Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
Phase 1 · 2 location(s) · Washington University School of Medicine · NCT06141031 PULSAR in Systemic Therapy for Pancreatic Cancer
Phase 2 · 1 location(s) · Samsung Medical Center · NCT07269626 Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable
Phase 1/Phase 2 · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT05688215 A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05851924 Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable
Phase 2 · 1 location(s) · Emory University · NCT06423326

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.